Over 25 years launching 15 medicines across 7 biopharmas, Frank F. Dolan mastered life science innovation. Transforming healthcare markets, introducing the GLP-1 class, and navigating billion dollar acquisitions required Frank to cast a vision of a future to compel others to believe, act, and execute. Currently he serves as founder and CEO of Arsenal Advisors, a media and intelligence firm serving biotech and pharma. His portfolio assets including MedicineToMarket.com and BioDataStudio reach 30k+ life-science executives each month influencing the decisions the shape the industry.
Personal website